Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 47

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 1B
Chunk 47
---
 of use assets

    16,167

    14,495

    12,735

    Non-cash interest expense

    4,951

    5,156

    7,552

    Stock-based compensation

    184,300

    182,514

    233,018

    Accretion of investment discount, net

    (40,277
    )

    (46,176
    )

    (10,651
    )

    Non-cash termination charges

    62,747

    —

    —

    Non-cash change in the fair value of derivatives

    7,838

    1,200

    (6,700
    )

    Impairment of strategic investments

    —

    30,321

    2,575

    Loss on debt extinguishment

    —

    387,329

    125,441

    Gain from sale of Priority Review Voucher

    —

    (102,000
    )

    —

    Other

    2,130

    (1,163
    )

    11,778

    Changes in operating assets and liabilities, net:

    Increase in accounts receivable

    (201,661
    )

    (185,699
    )

    (61,638
    )

    (Increase) decrease in manufacturing-related deposits and prepaids

    (188,588
    )

    (12,521
    )

    42,557

    Increase in inventory

    (395,170
    )

    (147,714
    )

    (50,780
    )

    (Increase) decrease in other assets

    (9,676
    )

    1,808

    (27,937
    )

    Decrease in deferred revenue

    (32,160
    )

    (86,828
    )

    (89,244
    )

    Increase (decrease) in accounts payable, accrued expenses,   lease liabilities and other liabilities

    110,649

    (50,135
    )

    147,572

    Net cash used in operating activities

    (205,787
    )

    (500,993
    )

    (325,346
    )

    Cash flows from investing activities:

    Purchase of property and equipment

    (136,956
    )

    (76,106
    )